Table 2.
Organs | iPSC-derived cells | Target disease or condition | Drug tested | Tests after drug exposure | OoC design elements | Days* | Vessels | Common medium | Material | Scaling | Ref. |
---|---|---|---|---|---|---|---|---|---|---|---|
Heart, liver | Heart: iPSC derived cardiomyocytes | Cardiotoxicity after drug hepatic metabolism | Cyclophosphamide, terfenadine, and fexofenadine | Heart: contractile force and electrical conductivity | Multi organ on a chip pumpless platform with integrated sensors for contractility and electrophysiology recording | 28 | N/A | Serum free medium | PDMS | N/A | Oleaga et al. 60 |
Heart, liver | Heart: iPSC derived cardiomyocytes | Drug induced hepatotoxicity/acute toxicity | (a) Acetaminophen (APAP) | Temperature, pH and O2 concentration, cell viability | Automated modular multi organoids on a chip platform with integrated pH, oxygen and temperature sensors, and electrochemical immunobiosensors | 5 | N/A | Cardiac basal medium (RPMI 1640) and hepatocytes medium (1:1 ratio) | PDMS and PMMA | Cell number ratio | Zhang et al. 63 |
Heart: cardiac biomarker secreted from the cardiac organoids, beating rate of the cardiac organoids | |||||||||||
(b) Doxorubicin (DOX) | |||||||||||
Liver: liver biomarkers secreted from hepatic organoids (a) and liver cancer organoids (b) | |||||||||||
Heart, liver | Heart: iPSC derived cardiomyocytes Liver: iPSC derived hepatocytes |
Hepatic metabolism-dependent cardiotoxicity | Clomipramine | Heart: cell viability, beating rate and velocity, intracellular calcium influx | Multi organoids on a chip | 9 | N/A | Cardiac medium (RPMI 1640 + B27) and hepatocytes medium (HCM + dexamethasone) (1:1 ratio) | PDMS | N/A | Yin et al. 58 |
Liver: cell viability, urea synthesis | |||||||||||
Differentiation and 3D co-culture of functional liver and heart organoids are simultaneous inside the platform | |||||||||||
Heart, liver, lung | Heart: iPSC derived cardiomyocytes | Liver: Acetaminophen (APAP) induced hepatotoxicity | APAP, APAP + N-acetyl-l-cysteine (NAC) | Cell viability, albumin and urea production, lactate dehydrogenase (LDH), and α-GST release | Multi organoids on a chip with integrated biosensors and 3D bioprinted cell constructs | 9 | Layers of endothelial cells forming a thin vascular barrier in the lung-on-a-chip module | α-MEM, FBS, l-glutamine, Pen/Strep | PDMS | Cell number ratio | Skardal et al. 61 |
Liver + Heart: drug induced toxicity | Epinephrine and propranolol | Cardiac organoid beat rates, cardiac organoid beat peaks, relative quantification of propranolol, and selected phase II metabolites | |||||||||
Liver+ Heart + Lung: lung inflammatory factor-driven cardiotoxicity | Bleomycin | Cell viability in 3-organoids platform, cardiac organoid beat rates, inflammatory response in 3-organoids platform |
Days in flow condition.